These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9369221)

  • 21. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest.
    Foster SA; Demers GW; Etscheid BG; Galloway DA
    J Virol; 1994 Sep; 68(9):5698-705. PubMed ID: 8057451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein.
    Chen JJ; Reid CE; Band V; Androphy EJ
    Science; 1995 Jul; 269(5223):529-31. PubMed ID: 7624774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.
    Huibregtse JM; Scheffner M; Howley PM
    EMBO J; 1991 Dec; 10(13):4129-35. PubMed ID: 1661671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6.
    Lagrange M; Charbonnier S; Orfanoudakis G; Robinson P; Zanier K; Masson M; Lutz Y; Trave G; Weiss E; Deryckere F
    J Gen Virol; 2005 Apr; 86(Pt 4):1001-1007. PubMed ID: 15784893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
    Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
    Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
    Mansur CP; Marcus B; Dalal S; Androphy EJ
    Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
    Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
    Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.
    Alarcón R; Koumenis C; Geyer RK; Maki CG; Giaccia AJ
    Cancer Res; 1999 Dec; 59(24):6046-51. PubMed ID: 10626788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53.
    Huibregtse JM; Scheffner M; Howley PM
    Mol Cell Biol; 1993 Feb; 13(2):775-84. PubMed ID: 8380895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surface plasmon resonance imaging protein arrays for analysis of triple protein interactions of HPV, E6, E6AP, and p53.
    Ro HS; Koh BH; Jung SO; Park HK; Shin YB; Kim MG; Chung BH
    Proteomics; 2006 Apr; 6(7):2108-11. PubMed ID: 16493710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6.
    Matsumoto Y; Nakagawa S; Yano T; Takizawa S; Nagasaka K; Nakagawa K; Minaguchi T; Wada O; Ooishi H; Matsumoto K; Yasugi T; Kanda T; Huibregtse JM; Taketani Y
    J Med Virol; 2006 Apr; 78(4):501-7. PubMed ID: 16482544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53-Dependent and -independent transactivation by the E6 protein of human papillomavirus type 16.
    Akutsu N; Shirasawa H; Asano T; Isono K; Simizu B
    J Gen Virol; 1996 Mar; 77 ( Pt 3)():459-63. PubMed ID: 8601782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background.
    Massimi P; Shai A; Lambert P; Banks L
    Oncogene; 2008 Mar; 27(12):1800-4. PubMed ID: 17934525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoexpression of mutant p53 and human papillomavirus related E6 oncoprotein in anal malignancies.
    Gupta S; Sharma BK
    Indian J Exp Biol; 1998 Sep; 36(9):875-8. PubMed ID: 9854426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
    Pim D; Massimi P; Banks L
    Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of p53 DNA binding by human papillomavirus E6 proteins.
    Lechner MS; Laimins LA
    J Virol; 1994 Jul; 68(7):4262-73. PubMed ID: 8207801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
    Stutz C; Reinz E; Honegger A; Bulkescher J; Schweizer J; Zanier K; Travé G; Lohrey C; Hoppe-Seyler K; Hoppe-Seyler F
    PLoS One; 2015; 10(7):e0132339. PubMed ID: 26151636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent.
    Tomaić V; Pim D; Banks L
    Virology; 2009 Oct; 393(1):7-10. PubMed ID: 19700180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation.
    Stöppler MC; Ching K; Stöppler H; Clancy K; Schlegel R; Icenogle J
    J Virol; 1996 Oct; 70(10):6987-93. PubMed ID: 8794343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53.
    Zanier K; ould M'hamed ould Sidi A; Boulade-Ladame C; Rybin V; Chappelle A; Atkinson A; Kieffer B; Travé G
    Structure; 2012 Apr; 20(4):604-17. PubMed ID: 22483108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.